Novartis Investigative Site

Atlantis, Florida 33462-6608

0 studies enrolling now · 9 studies all time

What they study most

Acute Heart Failure, Alzheimers Disease, Heart Failure With Reduced Ejection Fraction, Heart Failure and Reduced Ejection Fraction, Patients, Resistant Hypertension, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis — Completed
• A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. — Completed
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed